SCHEMBL3566923

SCHEMBL3566923

COc1ccccc1-c1cn(S(=O)(=O)c2ccc(C)cc2)c2ncc(-c3cc(F)c(C(N)=O)c(C(=O)N(C)C)c3)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.42
PTPN11 Q06124 1/20 0.41
MAPT P10636 3/20 0.39
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ABL1 P00519 2/20 0.38
KMT2A Q03164 4/20 0.36
MEN1 O00255 2/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
TGFBR1 P36897 2/20 0.32
ACVR1 Q04771 2/20 0.32
BRD4 O60885 1/20 0.32
CCNT1 O60563 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566926 0.91 MAP4K1 (0.45) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3563287 0.91 PTPN11 (0.43) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3565147 0.88 MAP4K1 (0.48) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3573801 0.87 PTPN11 (0.40) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3565148 0.86 MAP4K1 (0.59) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL13816796 0.86 MAP4K1 (0.40) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3565214 0.86 MAP4K1 (0.40) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3568791 0.84 PTPN11 (0.47) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL1516677 0.84 PTPN11 (0.43) MAP4K1PTPN11MAPTTSHRSMN1; SMN2
SCHEMBL3562857 0.84 MAP4K1 (0.39) MAP4K1PTPN11MAPTTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
EP-2134343-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 MAP4K1 3/4885PTPN11 1303/4885MAPT 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.